TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01862991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmotic cervical dilators inserted through the internal os.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmotic cervical dilators inserted through the internal os.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200 mcg Mifepristone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mcg Mifepristone orally
Study: NCT02047565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180mg edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 IU/kg Beriplex P/N

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 IU/kg Beriplex P/N

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 IU/kg Beriplex P/N
Study: NCT01015807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Placebo
Description: 2 x 20mL 0.9% NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Placebo
Description: 2 x 1mL 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Placebo
Description: 2 x 1mL 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 2 x 1ml Clonidine = 150 µg Clonidine
Study: NCT02819856

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg SPI-1005 bid po x 21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x1
Description: 200 mg SPI-1005 bid po x21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x2
Description: 400 mg SPI-1005 bid po x 21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x3
Description: 600 mg SPI-1005 bid po x 21d
Study: NCT02762344

Intervention type: DRUG
Intervention: heparin
Description: routinary heparin administration during coronary angiography/PCI

Intervention type: DRUG
Intervention: heparin
Description: routinary heparin administration during coronary angiography/PCI

Intervention type: DRUG
Intervention: heparin
Description: routinary heparin administration during coronary angiography/PCI
Study: NCT02075021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study: NCT03350113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood sampling for analysis
Description: Blood Sampling for Analysis
Study: NCT02839122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study: NCT03221504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longer therapy duration
Description: Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter therapy duration
Description: Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
Study: NCT03176095

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01114750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin in dextran matrix capsule (and placebo)
Description: Single dose capsule (and placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin in dextran matrix capsule (and placebo)
Description: Single dose capsule (and placebo)
Study: NCT01486615

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: meloset (melatonin)
Description: 3 mg melatonin tablet 1-2 hour prior surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: stresnil ( melatonin and alprazolam)
Description: 3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: (alprax) alprazolam
Description: 0.5 mg alprazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: similar looking placebo tablet
Study: NCT01999062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMRT + CT + MR scan
Study: NCT00794001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data analysis and Feedback
Description: Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
Study: NCT02444988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study: NCT03375125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
Study: NCT03465449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD-EDU
Description: Palliative Care based coaching intervention for support with dialysis-related decision making.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Nephrologist based usual care
Study: NCT04242420

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genotyping
Description: Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung function
Description: Spirometry,

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbiology
Description: Bacterial culture from Sputum or swab

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Interleukin-8 assay (via chemiluminescence) blood cell count

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Induced Sputum
Description: Interleukin-8 assay (via chemiluminescence) blood cell count
Study: NCT01040767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in basic ultrasound and the EFAST
Description: Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in basic ultrasound and the EFAST
Description: Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
Study: NCT04343443

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Description: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone interview
Description: Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study: NCT01517243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
Study: NCT01230606

Intervention type: OTHER
Intervention: discharge vs. overnight stay
Description: At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.

Intervention type: OTHER
Intervention: discharge vs. overnight stay
Description: At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
Study: NCT01383057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: Using the Femtosecond Laser to make a clear corneal incision.
Study: NCT03966079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator
Description: Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
Study: NCT01751815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo-TENS
Description: Patients randomized to the control group will receive placebo-TENS at the same acupoints.
Study: NCT02906085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline
Study: NCT02281175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a weekly physician intervention
Description: Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
Study: NCT03992885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle
Study: NCT03693274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BreathAware for Pain Management
Description: Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
Study: NCT03366220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced crystalloids
Description: Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
Study: NCT01250119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg daily, orally
Study: NCT03393338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DM I-TEAM
Description: DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
Study: NCT03303677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Nasal
Description: topical nasal saline rinses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Nasal
Description: topical nasal saline rinses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Nasal
Description: topical nasal saline rinses
Study: NCT03960866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: Topical Sterile Ophthalmic Solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study: NCT03275259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THORK Shock Wave® (Extracorporeal shock waves)
Description: Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
Study: NCT01864876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EM060G (SE)
Description: The same stable oil-in-water emulsion (SE), but without GLA.
Study: NCT03303677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: saline + budesonide nasal saline irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: saline + budesonide nasal saline irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibacterial (Product)
Description: The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
Study: NCT00708721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
Study: NCT04763655

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical and neuropsychological testing
Description: Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
Study: NCT01405417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Peroral Myotomy
Description: Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
Study: NCT01323595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg PO BID x 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill PO BID x 6 days
Study: NCT02340260

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High intensity interval training
Description: High intensity exercise during 12 weeks with three weekly training sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sprint interval training
Description: Sprint interval exercise during 12 weeks with three weekly training sessions
Study: NCT02715505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation with HSC835
Description: Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
Study: NCT00387751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT00743730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management for PNCA with basal method.
Description: Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management with PNCA without basal
Description: Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management with IV on an as needed basis method.
Description: Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol.
Study: NCT01246037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.